TrialPloS one2020

Immune recovery markers in a double blind clinical trial comparing dolutegravir and raltegravir based regimens as initial therapy (SPRING-2).

Jose-Ramon Blanco et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.